NEW YORK--(BUSINESS WIRE)--April 20, 2006--Axonyx Inc. (NASDAQ: AXYX - News) today reported on data showing an increase in brain glucose metabolism and reduction of brain amyloid levels in the memory and cognition areas in brains of mild-to-moderate Alzheimer's disease (AD) patients treated with Phenserine 15mg twice daily (BID) for 13-weeks. The data will be included in an oral presentation by Prof. Dr. Agneta Nordberg, MD, PhD of the Karolinska Institute, Stockholm, Sweden, on Friday, April 21st, 2006 at the 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy.
